+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

TNF Inhibitors - Global Strategic Business Report

  • PDF Icon

    Report

  • 191 Pages
  • December 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5309824
The global market for TNF Inhibitors was estimated at US$68.9 Billion in 2023, and is projected to reach US$106.9 Billion by 2030, growing at a CAGR of 6.5% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Rheumatoid Arthritis Application segment, which is expected to reach US$22.7 Billion by 2030 with a CAGR of a 8.3%. The Psoriasis Application segment is also set to grow at 6.6% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, estimated at $18.5 Billion in 2023, and China, forecasted to grow at an impressive 10.7% CAGR to reach $24.7 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global TNF Inhibitors Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global TNF Inhibitors Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global TNF Inhibitors Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of major players such as AbbVie Inc., Amgen Inc., Biocad Biopharmaceutical Co., and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 41 Featured):

  • AbbVie Inc.
  • Amgen Inc.
  • Biocad Biopharmaceutical Co.
  • Boehringer Ingelheim Pharmaceuticals, Inc.
  • EPIRUS Biopharmaceuticals, Inc.
  • Innovent Biologics, Inc.
  • Janssen Biotech, Inc.
  • Johnson & Johnson Services, Inc.
  • Merck & co., Inc.
  • Novartis International AG
  • Pfizer, Inc.
  • Shanghai Henlius Biotech, Inc.
  • UCB S.A.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • TNF Inhibitors - Global Key Competitors Percentage Market Share in 2024 (E)
  • Global Economic Update
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Increasing Prevalence of Autoimmune Diseases
  • Advancements in Biologic Therapies
  • Growing Demand for Targeted Therapies
  • Expansion of Biosimilars Market
  • Innovations in Drug Delivery Systems
  • Impact of Personalized Medicine on Treatment Approaches
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World TNF Inhibitors Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • Table 2: World Recent Past, Current & Future Analysis for TNF Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 3: World Historic Review for TNF Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 4: World 16-Year Perspective for TNF Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
  • Table 5: World Recent Past, Current & Future Analysis for Rheumatoid Arthritis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 6: World Historic Review for Rheumatoid Arthritis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 7: World 16-Year Perspective for Rheumatoid Arthritis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 8: World Recent Past, Current & Future Analysis for Psoriasis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 9: World Historic Review for Psoriasis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 10: World 16-Year Perspective for Psoriasis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 11: World Recent Past, Current & Future Analysis for Crohn’s Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 12: World Historic Review for Crohn’s Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 13: World 16-Year Perspective for Crohn’s Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 14: World Recent Past, Current & Future Analysis for Psoriatic Arthritis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 15: World Historic Review for Psoriatic Arthritis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 16: World 16-Year Perspective for Psoriatic Arthritis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 17: World Recent Past, Current & Future Analysis for Ulcerative Colitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 18: World Historic Review for Ulcerative Colitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 19: World 16-Year Perspective for Ulcerative Colitis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 20: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 21: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 22: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
  • TNF Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • Table 23: USA Recent Past, Current & Future Analysis for TNF Inhibitors by Application - Rheumatoid Arthritis, Psoriasis, Crohn’s Disease, Psoriatic Arthritis, Ulcerative Colitis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 24: USA Historic Review for TNF Inhibitors by Application - Rheumatoid Arthritis, Psoriasis, Crohn’s Disease, Psoriatic Arthritis, Ulcerative Colitis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 25: USA 16-Year Perspective for TNF Inhibitors by Application - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Psoriasis, Crohn’s Disease, Psoriatic Arthritis, Ulcerative Colitis and Other Applications for the Years 2014, 2024 & 2030
CANADA
  • Table 26: Canada Recent Past, Current & Future Analysis for TNF Inhibitors by Application - Rheumatoid Arthritis, Psoriasis, Crohn’s Disease, Psoriatic Arthritis, Ulcerative Colitis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 27: Canada Historic Review for TNF Inhibitors by Application - Rheumatoid Arthritis, Psoriasis, Crohn’s Disease, Psoriatic Arthritis, Ulcerative Colitis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 28: Canada 16-Year Perspective for TNF Inhibitors by Application - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Psoriasis, Crohn’s Disease, Psoriatic Arthritis, Ulcerative Colitis and Other Applications for the Years 2014, 2024 & 2030
JAPAN
  • TNF Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • Table 29: Japan Recent Past, Current & Future Analysis for TNF Inhibitors by Application - Rheumatoid Arthritis, Psoriasis, Crohn’s Disease, Psoriatic Arthritis, Ulcerative Colitis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 30: Japan Historic Review for TNF Inhibitors by Application - Rheumatoid Arthritis, Psoriasis, Crohn’s Disease, Psoriatic Arthritis, Ulcerative Colitis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 31: Japan 16-Year Perspective for TNF Inhibitors by Application - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Psoriasis, Crohn’s Disease, Psoriatic Arthritis, Ulcerative Colitis and Other Applications for the Years 2014, 2024 & 2030
CHINA
  • TNF Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • Table 32: China Recent Past, Current & Future Analysis for TNF Inhibitors by Application - Rheumatoid Arthritis, Psoriasis, Crohn’s Disease, Psoriatic Arthritis, Ulcerative Colitis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 33: China Historic Review for TNF Inhibitors by Application - Rheumatoid Arthritis, Psoriasis, Crohn’s Disease, Psoriatic Arthritis, Ulcerative Colitis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 34: China 16-Year Perspective for TNF Inhibitors by Application - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Psoriasis, Crohn’s Disease, Psoriatic Arthritis, Ulcerative Colitis and Other Applications for the Years 2014, 2024 & 2030
EUROPE
  • TNF Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • Table 35: Europe Recent Past, Current & Future Analysis for TNF Inhibitors by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 36: Europe Historic Review for TNF Inhibitors by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 37: Europe 16-Year Perspective for TNF Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
  • Table 38: Europe Recent Past, Current & Future Analysis for TNF Inhibitors by Application - Rheumatoid Arthritis, Psoriasis, Crohn’s Disease, Psoriatic Arthritis, Ulcerative Colitis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 39: Europe Historic Review for TNF Inhibitors by Application - Rheumatoid Arthritis, Psoriasis, Crohn’s Disease, Psoriatic Arthritis, Ulcerative Colitis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 40: Europe 16-Year Perspective for TNF Inhibitors by Application - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Psoriasis, Crohn’s Disease, Psoriatic Arthritis, Ulcerative Colitis and Other Applications for the Years 2014, 2024 & 2030
FRANCE
  • TNF Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • Table 41: France Recent Past, Current & Future Analysis for TNF Inhibitors by Application - Rheumatoid Arthritis, Psoriasis, Crohn’s Disease, Psoriatic Arthritis, Ulcerative Colitis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 42: France Historic Review for TNF Inhibitors by Application - Rheumatoid Arthritis, Psoriasis, Crohn’s Disease, Psoriatic Arthritis, Ulcerative Colitis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 43: France 16-Year Perspective for TNF Inhibitors by Application - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Psoriasis, Crohn’s Disease, Psoriatic Arthritis, Ulcerative Colitis and Other Applications for the Years 2014, 2024 & 2030
GERMANY
  • TNF Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • Table 44: Germany Recent Past, Current & Future Analysis for TNF Inhibitors by Application - Rheumatoid Arthritis, Psoriasis, Crohn’s Disease, Psoriatic Arthritis, Ulcerative Colitis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 45: Germany Historic Review for TNF Inhibitors by Application - Rheumatoid Arthritis, Psoriasis, Crohn’s Disease, Psoriatic Arthritis, Ulcerative Colitis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 46: Germany 16-Year Perspective for TNF Inhibitors by Application - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Psoriasis, Crohn’s Disease, Psoriatic Arthritis, Ulcerative Colitis and Other Applications for the Years 2014, 2024 & 2030
ITALY
  • Table 47: Italy Recent Past, Current & Future Analysis for TNF Inhibitors by Application - Rheumatoid Arthritis, Psoriasis, Crohn’s Disease, Psoriatic Arthritis, Ulcerative Colitis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 48: Italy Historic Review for TNF Inhibitors by Application - Rheumatoid Arthritis, Psoriasis, Crohn’s Disease, Psoriatic Arthritis, Ulcerative Colitis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 49: Italy 16-Year Perspective for TNF Inhibitors by Application - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Psoriasis, Crohn’s Disease, Psoriatic Arthritis, Ulcerative Colitis and Other Applications for the Years 2014, 2024 & 2030
UNITED KINGDOM
  • TNF Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • Table 50: UK Recent Past, Current & Future Analysis for TNF Inhibitors by Application - Rheumatoid Arthritis, Psoriasis, Crohn’s Disease, Psoriatic Arthritis, Ulcerative Colitis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 51: UK Historic Review for TNF Inhibitors by Application - Rheumatoid Arthritis, Psoriasis, Crohn’s Disease, Psoriatic Arthritis, Ulcerative Colitis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 52: UK 16-Year Perspective for TNF Inhibitors by Application - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Psoriasis, Crohn’s Disease, Psoriatic Arthritis, Ulcerative Colitis and Other Applications for the Years 2014, 2024 & 2030
SPAIN
  • Table 53: Spain Recent Past, Current & Future Analysis for TNF Inhibitors by Application - Rheumatoid Arthritis, Psoriasis, Crohn’s Disease, Psoriatic Arthritis, Ulcerative Colitis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 54: Spain Historic Review for TNF Inhibitors by Application - Rheumatoid Arthritis, Psoriasis, Crohn’s Disease, Psoriatic Arthritis, Ulcerative Colitis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 55: Spain 16-Year Perspective for TNF Inhibitors by Application - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Psoriasis, Crohn’s Disease, Psoriatic Arthritis, Ulcerative Colitis and Other Applications for the Years 2014, 2024 & 2030
RUSSIA
  • Table 56: Russia Recent Past, Current & Future Analysis for TNF Inhibitors by Application - Rheumatoid Arthritis, Psoriasis, Crohn’s Disease, Psoriatic Arthritis, Ulcerative Colitis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 57: Russia Historic Review for TNF Inhibitors by Application - Rheumatoid Arthritis, Psoriasis, Crohn’s Disease, Psoriatic Arthritis, Ulcerative Colitis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 58: Russia 16-Year Perspective for TNF Inhibitors by Application - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Psoriasis, Crohn’s Disease, Psoriatic Arthritis, Ulcerative Colitis and Other Applications for the Years 2014, 2024 & 2030
REST OF EUROPE
  • Table 59: Rest of Europe Recent Past, Current & Future Analysis for TNF Inhibitors by Application - Rheumatoid Arthritis, Psoriasis, Crohn’s Disease, Psoriatic Arthritis, Ulcerative Colitis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 60: Rest of Europe Historic Review for TNF Inhibitors by Application - Rheumatoid Arthritis, Psoriasis, Crohn’s Disease, Psoriatic Arthritis, Ulcerative Colitis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 61: Rest of Europe 16-Year Perspective for TNF Inhibitors by Application - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Psoriasis, Crohn’s Disease, Psoriatic Arthritis, Ulcerative Colitis and Other Applications for the Years 2014, 2024 & 2030
ASIA-PACIFIC
  • TNF Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • Table 62: Asia-Pacific Recent Past, Current & Future Analysis for TNF Inhibitors by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 63: Asia-Pacific Historic Review for TNF Inhibitors by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 64: Asia-Pacific 16-Year Perspective for TNF Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
  • Table 65: Asia-Pacific Recent Past, Current & Future Analysis for TNF Inhibitors by Application - Rheumatoid Arthritis, Psoriasis, Crohn’s Disease, Psoriatic Arthritis, Ulcerative Colitis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 66: Asia-Pacific Historic Review for TNF Inhibitors by Application - Rheumatoid Arthritis, Psoriasis, Crohn’s Disease, Psoriatic Arthritis, Ulcerative Colitis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 67: Asia-Pacific 16-Year Perspective for TNF Inhibitors by Application - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Psoriasis, Crohn’s Disease, Psoriatic Arthritis, Ulcerative Colitis and Other Applications for the Years 2014, 2024 & 2030
AUSTRALIA
  • TNF Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
INDIA
  • TNF Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
SOUTH KOREAREST OF ASIA-PACIFIC
LATIN AMERICA
  • TNF Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
ARGENTINABRAZILMEXICOREST OF LATIN AMERICA
MIDDLE EAST
  • TNF Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST
AFRICA
  • TNF Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
IV. COMPETITION

Companies Mentioned

  • AbbVie Inc.
  • Amgen Inc.
  • Biocad Biopharmaceutical Co.
  • Boehringer Ingelheim Pharmaceuticals, Inc.
  • EPIRUS Biopharmaceuticals, Inc.
  • Innovent Biologics, Inc.
  • Janssen Biotech, Inc.
  • Johnson & Johnson Services, Inc.
  • Merck & co., Inc.
  • Novartis International AG
  • Pfizer, Inc.
  • Shanghai Henlius Biotech, Inc.
  • UCB S.A.

Table Information